Metabolic syndrome and rare gynecological cancers in the Metabolic syndrome and Cancer project (Me-Can)
(2011) In Annals of Oncology 22(6). p.1339-1345- Abstract
- Background: Risk factors for rare gynecological cancers are largely unknown. Initial research has indicated that the metabolic syndrome (MetS) or individual components could play a role. Materials and methods: The Metabolic syndrome and Cancer project cohort includes 288 834 women. During an average follow-up of 11 years, 82 vulvar, 26 vaginal and 43 other rare gynecological cancers were identified. Hazard ratios (HRs) were estimated fitting Cox proportional hazards regression models for tertiles and standardized z-scores [with a mean of 0 and a standard deviation (SD) of 1] of body mass index (BMI), blood pressure, glucose, cholesterol, triglycerides and MetS. Risk estimates were corrected for random error in the measurement of metabolic... (More)
- Background: Risk factors for rare gynecological cancers are largely unknown. Initial research has indicated that the metabolic syndrome (MetS) or individual components could play a role. Materials and methods: The Metabolic syndrome and Cancer project cohort includes 288 834 women. During an average follow-up of 11 years, 82 vulvar, 26 vaginal and 43 other rare gynecological cancers were identified. Hazard ratios (HRs) were estimated fitting Cox proportional hazards regression models for tertiles and standardized z-scores [with a mean of 0 and a standard deviation (SD) of 1] of body mass index (BMI), blood pressure, glucose, cholesterol, triglycerides and MetS. Risk estimates were corrected for random error in the measurement of metabolic factors. Results: The MetS was associated with increased risk of vulvar [HR 1.78, 95% confidence interval (CI) 1.30-2.41) and vaginal cancer (HR 1.87, 95% CI 1.07-3.25). Among separate MetS components, 1 SD increase in BMI was associated with overall risk (HR 1.43, 95% CI 1.23-1.66), vulvar (HR 1.36, 95% CI 1.11-1.69) and vaginal cancer (HR 1.79, 95% CI 1.30-2.46). Blood glucose and triglyceride concentrations were associated with increased risk of vulvar cancer (HR 1.98, 95% CI 1.10-3.58 and HR 2.09, 95% CI 1.39-3.15, respectively). Conclusion: The results from this first prospective study on rare gynecological cancers suggest that the MetS and its individual components may play a role in the development of these tumors. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1985641
- author
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- epidemiology, MetS, rare gynecological cancers
- in
- Annals of Oncology
- volume
- 22
- issue
- 6
- pages
- 1339 - 1345
- publisher
- Oxford University Press
- external identifiers
-
- wos:000291060800014
- scopus:79957849240
- pmid:20966183
- ISSN
- 1569-8041
- DOI
- 10.1093/annonc/mdq597
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200), Surgery Research Unit (013242220)
- id
- 0fc2029c-851c-4a3a-90fb-7f3e852ed4b0 (old id 1985641)
- date added to LUP
- 2016-04-01 13:31:44
- date last changed
- 2022-02-04 07:57:42
@article{0fc2029c-851c-4a3a-90fb-7f3e852ed4b0, abstract = {{Background: Risk factors for rare gynecological cancers are largely unknown. Initial research has indicated that the metabolic syndrome (MetS) or individual components could play a role. Materials and methods: The Metabolic syndrome and Cancer project cohort includes 288 834 women. During an average follow-up of 11 years, 82 vulvar, 26 vaginal and 43 other rare gynecological cancers were identified. Hazard ratios (HRs) were estimated fitting Cox proportional hazards regression models for tertiles and standardized z-scores [with a mean of 0 and a standard deviation (SD) of 1] of body mass index (BMI), blood pressure, glucose, cholesterol, triglycerides and MetS. Risk estimates were corrected for random error in the measurement of metabolic factors. Results: The MetS was associated with increased risk of vulvar [HR 1.78, 95% confidence interval (CI) 1.30-2.41) and vaginal cancer (HR 1.87, 95% CI 1.07-3.25). Among separate MetS components, 1 SD increase in BMI was associated with overall risk (HR 1.43, 95% CI 1.23-1.66), vulvar (HR 1.36, 95% CI 1.11-1.69) and vaginal cancer (HR 1.79, 95% CI 1.30-2.46). Blood glucose and triglyceride concentrations were associated with increased risk of vulvar cancer (HR 1.98, 95% CI 1.10-3.58 and HR 2.09, 95% CI 1.39-3.15, respectively). Conclusion: The results from this first prospective study on rare gynecological cancers suggest that the MetS and its individual components may play a role in the development of these tumors.}}, author = {{Nagel, G. and Concin, H. and Bjorge, T. and Rapp, K. and Manjer, Jonas and Hallmans, G. and Diem, G. and Haggstrom, C. and Engeland, A. and Almquist, Martin and Jonsson, H. and Selmer, R. and Stocks, T. and Tretli, S. and Ulmer, H. and Stattin, P. and Lukanova, A.}}, issn = {{1569-8041}}, keywords = {{epidemiology; MetS; rare gynecological cancers}}, language = {{eng}}, number = {{6}}, pages = {{1339--1345}}, publisher = {{Oxford University Press}}, series = {{Annals of Oncology}}, title = {{Metabolic syndrome and rare gynecological cancers in the Metabolic syndrome and Cancer project (Me-Can)}}, url = {{http://dx.doi.org/10.1093/annonc/mdq597}}, doi = {{10.1093/annonc/mdq597}}, volume = {{22}}, year = {{2011}}, }